Clinical trials: sponsored by Boehringer Ingelheim
Asthma
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
The safety of Spiriva® 2.5 µg Respimat® 60 puffs (hereinafter referred to as Spiriva® Respimat®) in patients with severe persistent asthma under the real-world use was not confirmed in clinical trials.
- Trial name
- NCT02489981
- Testing
- Spiriva
- Where
- Brazil
- Volunteers
- 359 people
- Sponsor
- Boehringer Ingelheim
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
To investigate the maximum tolerated dose (MTD), safety, pharmacokinetics, and efficacy of volasertib in combination with azacitidine in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) and…
- Trial name
- NCT01957644
- Testing
- Azacitidine, Volasertib
- Where
- 14 sites in France, Germany
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF)
- Trial name
- NCT02230982
- Testing
- nintedanib
- Where
- 8 sites in Brazil
- Sponsor
- Boehringer Ingelheim
Psoriasis
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
To evaluate the efficacy and to compare efficacy and safety of BI 695501 versus Humira in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02850965
- Testing
- BI 695501, Humira
- Where
- 54 sites in United States, Czechia and 6 more
- Volunteers
- 318 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of the combination of BI 6727 with BIBW 2992, in patients with advanced or metastatic solid…
- Trial name
- NCT01206816
- Testing
- BI 6727 + BIBW 2992
- Where
- 3 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events when combined with a platinum therapy (cisplatin or carboplatin).
- Trial name
- NCT00969761
- Testing
- BI-6727, BI 6727
- Where
- 2 sites in Belgium
- Volunteers
- 61 people
- Sponsor
- Boehringer Ingelheim
Leukemia, Myeloid, Acute
Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)
Dose Escalation (MTD Finding) Phase: To investigate the maximum tolerated dose (MTD), safety and pharmacokinetics of different volasertib administration schedules in combination with decitabine in previously untreated AML…
- Trial name
- NCT02003573
- Testing
- decitabine iv, volasertib iv infusion
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
Investigation of absorption, distribution, metabolism and excretion (ADME) and assessment of safety, tolerability and preliminary therapeutic effects of [14C]volasertib in patients with advanced solid tumours.
- Trial name
- NCT01145885
- Testing
- BI 6727
- Where
- Hungary
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Characteristics of Empagliflozin Initiators
Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in their characteristics from…
- Trial name
- NCT03050619
- Testing
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- Where
- Germany
- Volunteers
- 31,908 people
- Sponsor
- Boehringer Ingelheim
Non-alcoholic Fatty Liver Disease
Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
The primary objective of this trial is to investigate the relative Bioavailability (BA) of tablet formulation of Dabigatran etexilate (DE) with and without co-administration of rabeprazole in healthy male subjects.
- Trial name
- NCT03143166
- Testing
- Dabigatran Etexilate, Rabeprazol sodium
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.
- Trial name
- NCT02802345
- Testing
- Nintedanib, Sildenafil
- Where
- 85 sites in United States, Australia and 11 more
- Volunteers
- 274 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus
The aim of this study is to monitor safety and efficacy of treatment with linagliptin in Korean patients with type 2 diabetes mellitus in routine clinical settings.
- Trial name
- NCT01707147
- Testing
- Trajenta tablet
- Where
- South Korea
- Volunteers
- 3,219 people
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects
The primary objective of this trial is to establish the bioequivalence of tablet formulation of dabigatran etexilate compared to commercial capsule formulation following oral administration under fasted condition.
- Trial name
- NCT03070171
- Testing
- dabigatran etexilate
- Where
- Japan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)
Real-world data on the effects of a fixed-dose combination Long-acting beta agonists + long-acting antimuscarinic agent (LABA+LAMA) therapy with tiotropium and olodaterol administered in a single device, in COPD patients who need…
- Trial name
- NCT02719639
- Where
- 9 sites in Austria, Czechia and 7 more
- Volunteers
- 7,443 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
- Trial name
- NCT02589626
- Testing
- empagliflozin 10mg, empagliflozin 25 mg
- Where
- 16 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
The primary objective of the trial is to determine the maximum tolerated doses (MTD) of BI 860585 alone and in combination with exemestane or paclitaxel.
- Trial name
- NCT01938846
- Testing
- BI 860585, exemestane, paclitaxel
- Where
- 4 sites in Belgium, Italy
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin regimen of multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII).
- Trial name
- NCT02414958
- Testing
- Empagliflozin
- Where
- 131 sites in United States, Australia and 15 more
- Volunteers
- 730 people
- Sponsor
- Boehringer Ingelheim
Healthy
Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector
To investigate and compare the pharmacokinetics, safety and tolerability of BI 695501 administered subcutaneously via prefilled syringe or autoinjector
- Trial name
- NCT02606903
- Testing
- BI 695501 prefilled syringe, BI 695501 autoinjector
- Where
- Belgium
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea
The primary objective of this study is to monitor the safety profile of Trajenta Duo in Korean patients with type 2 diabetes mellitus (T2DM) in a routine clinical setting.
- Trial name
- NCT01903356
- Testing
- Trajenta duo
- Where
- South Korea
- Volunteers
- 724 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
Monotherapy Dose Finding With BI 847325 in Solid Tumours
The aim of the Phase Ia (dose escalation) part of this trial is to assess the maximum tolerated dose (MTD) of BI 847325 administered at escalating doses in 2 treatment arms.
- Trial name
- NCT01324830
- Testing
- day 1 to day 5, day 1 to day 14
- Where
- 2 sites in Belgium
- Volunteers
- 69 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.